Projecting future drug expenditures - 2003

American Journal of Health-System Pharmacy

Volumn 60, Issue 2, 2003, Pages 137-149

  Shah, Nilay D ^a,b   Hoffman, James M ^c   Vermeulen, Lee C ^a,d   Hunkler, Robert J ^e   Hontz, Karrie M ^e  

^a University of Wisconsin Health   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UWHC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e IQVIA   (United States)

Author keywords

Ambulatory care; Antiinflammatory agents; Antiretroviral agents; Budgets; Cardiac drugs; Costs; Drotrecogin alfa; Drug use; Drugs; Economics; Enfuvirtid; Health care; HIV infections; Hospitals; Nesiritide; Prescriptions; Pricing

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFLAMMATORY AGENT; ATAZANAVIR; AZIMILIDE; DROTRECOGIN; DULOXETINE; EFALIZUMAB; ELETRIPTAN; EMTRICITABINE; ENFUVIRTIDE; EPRATUZUMAB; ERLOTINIB; FLUOXETINE; GEFITINIB; GENERIC DRUG; ILOPERIDONE; LERCANIDIPINE; LEVOSIMENDAN; LISINOPRIL; LUMIRACOXIB; MEMANTINE; METFORMIN; NATALIZUMAB; OLANZAPINE; OMALIZUMAB; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TEMSIROLIMUS; UNINDEXED DRUG;

ALZHEIMER DISEASE; ASTHMA; BUDGET; CONGESTIVE HEART FAILURE; DEPRESSION; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FINANCING; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAID; MEDICARE; MIGRAINE; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OSTEOARTHRITIS; OUTPATIENT CARE; PATENT; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; UNITED STATES;

EID: 0242416916     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.2.137     Document Type: Review

References (46)

1. Centers for Medicare & Medicaid Services. Health accounts. www.cms.hhs.gov/statistics/nhe/ (accessed 2002 Aug 4).
2. Kaiser Family Foundation. Prescription drug trends - a chartbook update. Nov 2001. www.kff.org (accessed 2002 Jul 24).
3. Hospital statistics, 2002. Chicago: American Hospital Association; 2002.
4. Strunk BC, Ginsburg PB, Gabel JR. Tracking health care costs: growth accelerates again in 2001. Health Aff. 2002; W299-310.
5. Data trends - direct expense percentage by department. Healthc Financ Manage. 2001; 55:84.
6. Heffler S, Smith S, Won G et al. Health spending projections for 2001-2011: the latest outlook. Health Aff. 2002; 21:207-18.
7. IMS HEALTH Retail and Provider Perspective. 2002 Jul.
8. IMS HEALTH National Prescription Audit. 2002 Aug.
9. Blankenhorn K, Lipson D. Business watch 2001 in review. Med Mark Media. 2002; 37:46-62.
10. Shah ND, Vermeulen LC, Santell JP et al. Projecting drug expenditures - 2002. Am J Health-Syst Pharm. 2002; 59:131-42.
11. Prescription drug expenditures in 2001: another year of escalating costs. Washington, DC: National Institute for Health Care Management; 2002 Apr.
12. 2001 Drug trend report. St. Louis: Express Scripts; 2002 Jun.
13. Halbert RJ, Zaher C, Wade S et al. Outpatient cancer drug costs: changes, drivers, and the future. Cancer. 2002; 94:1142-50.
14. Caron MF, Kluger J, White MC. Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias. Ann Pharmacother. 2001; 35:1248-54.
15. Tucker GT. Chiral switches. Lancet. 2000; 355:1085-7.
16. Otto A. We're not gonna take it. Wash Post. 2002; Mar 26:HE01.
17. Food and Drug Administration. New drug approval reports. www.fda.gov/cder/rdmt/ (accessed 2002 Sep 4).
18. Pollack A. Despite billions for discoveries, pipeline of drugs is far from full. N Y Times. 2002; Apr 19:C1.
19. Waltz JA, Ung D, Allen ME. Drug prices likely to rise with more regulatory oversight of clinical research programs. Drug Benefit Trends. 2002; 14:13-4.
20. NDA filing slowdown continues; FDA has received 16 NMEs in FY 2002. FDC Rep. 2002; (Sep 16):16.
21. Peltz M. Getting to yes. Worth. Sep 2002:45-7.
22. Food and Drug Administration. New drug approval time: the facts.www.fda.gov/oc/pdufa/thefacts/default.htm (accessed 2002 Sep 4).
23. Food and Drug Administration. FDA approves eloxatin for colorectal cancer. www.fda.gov/bbs/topics/NEWS/2002/NEW00825.html (accessed 2002 Sep 3).
24. Levy JH, Goodnough LT, Greilich PE et al. Polymerized bovine hemoglobin solution as a replacement for allogenic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg. 2002; 124:35-42.
25. Krasner J. Positive or negative? Investors hope FDA filing yields key data on Hemopure. Boston Globe. 2002; Jul 31:C1.
26. Krasner J. Biopure gets grant for Hemopure trial; $908,900 allows firm to conduct testing for army. Boston Globe. 2002; Sep 5:C7.
27. Price JH. Experimental AIDS drug hoped to lengthen lives. New class of medication reaches virus before cell infection. Wash Times. 2002; Aug 23:A03.
28. Russell S. AIDS drug funds drying up for uninsured Americans: state programs going broke as economy slumps and costly drugs appear. San Francisco Chronicle. 2002; Jul 29:A11.
29. Shook D. A shock to Lilly's system. BusinessWeek Online. www.businessweek.com/bwdaily/dnflash/mar2002/nf2002037_2428.htm (accessed 2002 Sep 7).
30. Firm faces summertime blues: Eli Lilly is losing its Prozac patent. Cincinnati Post. 2001; Jul 12:9C.
31. Matthay MA. Severe sepsis - a new treatment with both anticoagulant and anti-inflammatory properties. N Engl J Med. 2001; 344:759-62.
32. Traynor K. High-cost sepsis drug forces pharmacists to weigh patients' future. Am J Health-Syst Pharm. 2002; 59:692,697.
33. Bernard GR, Vincent JL, Laterre PF et al., for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001; 344:699-709.
34. Centers for Medicare & Medicaid Services. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2003 rates. Final rule. Fed Regist. 2002; 67:49981-50289.
35. Xigris Medicare "add-on" payments approved; CMS estimates 50,000 cases. FDC Rep. 2002; (Aug 5):18-9.
36. Stock up on cardiology; higher demand is coming. Hosp Mater Manage. 2002; 27:2.
37. Oncology diagnoses will increase 9% by 2006; hospitals will reallocate mix of beds and services. Health Care Strateg Manage. 2002; 20(5):9.
38. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235-42.
39. Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002; 73:100-4.
40. Becker YT, Becker BN, Pirsch JD et al. Successful use of rituximab for high-risk transplantation and rejection. Transplantation. 2002; 74(suppl):437. Abstract.
41. Castel-DesHarnais L, Bajwa K, Markle JP et al. A microcosting analysis of zolendronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001; 9:545-51.
42. Medicare OPPS "pass-through" payments set for Neulasta, Zevalin, Invanz. FDA Rep. 2002; (Aug 12):24-5.
43. Suh D, Manning WG, Schondelmeyer S et al. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res. 2000; 35:529-47.
44. Harris G. Drug prices - why they keep soaring. Wall S J. 2002; Jun 6:A1.
45. Rozek RP, Berkowitz R. The costs to the U.S. health care system of extending marketing exclusivity for Taxol. J Res Pharm Econ. 1999; 9:21-41.
46. Goldstein A. Health care woes boost generics bill: when House gets its turn, benefits to brand name drug makers could erode. Wash Post. 2002; Aug 16:A23.